Search research articles
Contact Us
Filters
Showing results (71-80 of 82) with videos related to
Page
of 9
Sort By:
The Lancet. Oncology
|
June 9, 2019
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E Cortes, Samer Khaled, Giovanni Martinelli, et al.
Blood
|
August 18, 2023
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
Sylvie D Freeman, Abin Thomas, Ian Thomas, et al.
Frontiers in Microbiology
|
June 14, 2021
Respiratory Co-Infections: Modulators of SARS-CoV-2 Patients' Clinical Sub-Phenotype
Priyanka Mehta, Shweta Sahni, Samreen Siddiqui, et al.
Frontiers in Immunology
|
November 15, 2021
Plasma Gradient of Soluble Urokinase-Type Plasminogen Activator Receptor Is Linked to Pathogenic Plasma Proteome and Immune Transcriptome and Stratifies Outcomes in Severe COVID-19
Jafar Sarif, Deblina Raychaudhuri, Ranit D'Rozario, et al.
Plos One
|
March 17, 2022
COVID-19 Risk Stratification and Mortality Prediction in Hospitalized Indian Patients: Harnessing clinical data for public health benefits
Shanmukh Alle, Akshay Kanakan, Samreen Siddiqui, et al.
Blood
|
November 14, 2025
CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18
Steven Knapper, Laura W Dillon, Malavika Babu, et al.
Blood Advances
|
February 6, 2025
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Adriano Venditti, Raffaele Palmieri, Luca Maurillo, et al.
Blood
|
August 30, 2023
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy
Jad Othman, Ing S Tiong, Jenny O'Nions, et al.
Blood
|
January 15, 2020
Molecular MRD status and outcome after transplantation in NPM1-mutated AML
Richard Dillon, Robert Hills, Sylvie Freeman, et al.
Blood Neoplasia
|
June 2, 2025
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS
Jad Othman, Ho Pui Jeff Lam, Sarah Leong, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 82) with videos related to
Sort By:
Page
of 9
The Lancet. Oncology
|
June 9, 2019
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E Cortes, Samer Khaled, Giovanni Martinelli, et al.
Blood
|
August 18, 2023
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
Sylvie D Freeman, Abin Thomas, Ian Thomas, et al.
Frontiers in Microbiology
|
June 14, 2021
Respiratory Co-Infections: Modulators of SARS-CoV-2 Patients' Clinical Sub-Phenotype
Priyanka Mehta, Shweta Sahni, Samreen Siddiqui, et al.
Frontiers in Immunology
|
November 15, 2021
Plasma Gradient of Soluble Urokinase-Type Plasminogen Activator Receptor Is Linked to Pathogenic Plasma Proteome and Immune Transcriptome and Stratifies Outcomes in Severe COVID-19
Jafar Sarif, Deblina Raychaudhuri, Ranit D'Rozario, et al.
Plos One
|
March 17, 2022
COVID-19 Risk Stratification and Mortality Prediction in Hospitalized Indian Patients: Harnessing clinical data for public health benefits
Shanmukh Alle, Akshay Kanakan, Samreen Siddiqui, et al.
Blood
|
November 14, 2025
CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18
Steven Knapper, Laura W Dillon, Malavika Babu, et al.
Blood Advances
|
February 6, 2025
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Adriano Venditti, Raffaele Palmieri, Luca Maurillo, et al.
Blood
|
August 30, 2023
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy
Jad Othman, Ing S Tiong, Jenny O'Nions, et al.
Blood
|
January 15, 2020
Molecular MRD status and outcome after transplantation in NPM1-mutated AML
Richard Dillon, Robert Hills, Sylvie Freeman, et al.
Blood Neoplasia
|
June 2, 2025
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS
Jad Othman, Ho Pui Jeff Lam, Sarah Leong, et al.
Page
of 9